UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 451

Sortiert nach

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of oncology, 2021-08, Vol.32 (8), p.1015-1024

2021

Volltextzugriff (PDF)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.719-729

2019

Volltextzugriff (PDF)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of oncology, 2018-04, Vol.29 (4), p.888-894

2018

Volltextzugriff (PDF)

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Annals of oncology, 2022-03, Vol.33 (3), p.321-329

2022

Volltextzugriff (PDF)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Breast cancer research : BCR, 2023-08, Vol.25 (1), p.1-103, Article 103

2023

Volltextzugriff (PDF)

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.739-749

2004

Volltextzugriff (PDF)

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

JNCI : Journal of the National Cancer Institute, 2003-01, Vol.95 (2), p.142-153

2003

Volltextzugriff (PDF)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

British journal of cancer, 2014-10, Vol.111 (9), p.1788-1801

2014

Volltextzugriff (PDF)

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.759-769

2004

Volltextzugriff (PDF)

FOXA1 represses the molecular phenotype of basal breast cancer cells

Oncogene, 2013-01, Vol.32 (5), p.554-563

2013

Volltextzugriff (PDF)

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

Annals of oncology, 2023-11, Vol.34 (11), p.1003-1014

2023

Volltextzugriff (PDF)

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Annals of oncology, 2005-11, Vol.16 (11), p.1772-1777

2005

Volltextzugriff (PDF)

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2639-2648

1999

Volltextzugriff (PDF)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

British journal of cancer, 2009-11, Vol.101 (10), p.1699-1708

2009

Volltextzugriff (PDF)

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Gynecologic oncology, 2023-03, Vol.170, p.221-228

2023

Volltextzugriff (PDF)

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Annals of oncology, 2006-04, Vol.17 (4), p.597-604

2006

Volltextzugriff (PDF)

Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]

Annals of oncology, 2023-07, Vol.34 (7), p.630-630

2023

Volltextzugriff (PDF)

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

Gynecologic oncology, 2021-12, Vol.163 (3), p.465-472

2021

Volltextzugriff (PDF)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

British journal of cancer, 2008-03, Vol.98 (6), p.1076-1084

2008

Volltextzugriff (PDF)

Rationale for trastuzumab (herceptin) in adjuvant breast cancer trials

Seminars in oncology, 2001-02, Vol.28 (1D), p.13-19, Article asonc0280013d

2001

Volltextzugriff (PDF)

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Annals of oncology, 2016-06, Vol.27 (6), p.1029-1034

2016

Volltextzugriff (PDF)

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

The New England journal of medicine, 2001-03, Vol.344 (11), p.783-792

2001

Volltextzugriff (PDF)

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

Annals of oncology, 2011-01, Vol.22 (1), p.68-73

2011

Volltextzugriff (PDF)

Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins

The American journal of pathology, 2001-11, Vol.159 (5), p.1645-1650

2001

Volltextzugriff (PDF)

1 – 25 von 451

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(446)
Mit Volltextzugriff
(424)

Publikationsform

Artikel
(447)
Tagungsberichte
(4)

Sprache

Englisch
(450)
Japanisch
(56)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

FOXA1 represses the molecular phenotype of basal breast cancer cells

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

Rationale for trastuzumab (herceptin) in adjuvant breast cancer trials

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins

Suchergebnisse filtern